Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

COUGH-1 and COUGH-2 Investigators

Research output: Contribution to journal › Article › peer-review

132 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences